Pharmaceutical Technology

DECEMBER 22, 2022

Below you can find all the winners from the 2022 Excellence Awards which celebrate the greatest achievements and innovations in the industry. However in 2022 it achieved two further groundbreaking approvals for recurrent or metastatic HER2-low breast cancer, and previously treated, HER2-mutant non-small cell lung cancer (NSCLC).

Diabetes 52

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 31, 2022

German injectable medicines specialist Fresenius Kabi has made a pair of deals to kickstart its new strategic direction, including a majority stake in mAbxience that bolsters its position in biosimilars. The post Deals build Fresenius Kabi’s position in biosimilars, medtech appeared first on.

Biosimilars 52

Biosimilars Vaccines 52

Drug Channels

FEBRUARY 22, 2022

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices. Special preorder and launch pricing discounts will be valid through March 28, 2022.

Specialty Pharmacies 96

Specialty Pharmacies Drug Pricing Biosimilars Vaccines 96

pharmaphorum

FEBRUARY 3, 2022

There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. Delve into the world of biologics and biosimilars and what these mean for the injectable drug market. The post Injectable Drug Delivery 2022 appeared first on. KG; Zealand Pharma A/S.

Compounding 52

Compounding Packaging Biosimilars Vaccines 52

Express Pharma

JUNE 28, 2024

Both India and Turkey are rising in this field, presenting significant trade and cooperation opportunities In 2022, the global pharmaceutical market reached a value of $ 1.5 The significant growth in biosimilars approvals and manufacturing further enhances patient access to biopharmaceuticals. trillion, with Turkey ranking 21st.

Packaging 105

Packaging Biosimilars Labelling Vaccines 105

pharmaphorum

FEBRUARY 3, 2022

Roche has warned that revenue growth will come under pressure in the coming year as sales of its COVID-19 testing kits start to slow, exposing the impact of biosimilar competition to some of its top-selling drugs. billion) in 2022 from CHF 7 billion last year, with another CHF 2.5 billion and CHF 1.63

Biosimilars 52

Biosimilars Vaccines 52

European Pharmaceutical Review

JANUARY 9, 2023

Global M&A activity in 2022. The global life sciences mergers and acquisitions (M&A) investment totalled $105 billion in the first 11 months of 2022, with total deal value well down on 2021. EY’s research observed an overall drop in 2022 M&A investment worldwide. Biopharma alone held over $1.4

Biosimilars 98

Biosimilars Vaccines 98

pharmaphorum

AUGUST 25, 2022

The Swiss pharma group said this morning that the separation “is in the best interest of shareholders” and will create the number one generics company in Europe and a leader in biosimilars, whilst allowing Novartis to focus on its patented medicines business. billion by 2024.

Biosimilars 105

Biosimilars Compounding Vaccines 105

Pharmaceutical Technology

JANUARY 30, 2023

However, two successive years of unusually high branded medicine sales figures, following the COVID-19 pandemic and a major post-lockdown surge in demand, have distorted the original model, causing a massive hike in payback rates, first capped at 15% in 2022, then jumping to 26.5% In 2022, a proposed payback figure of 19.1%

Biosimilars 97

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Vaccines 97

Pharmaceutical Technology

JANUARY 30, 2023

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. However, non-NME and biosimilar approvals increased in 2022. This is due to generally more stringent criteria on approvals in the wake of the Aduhelm scandal. months longer on the treatment.

Biosimilars 52

Biosimilars Diabetes Chemotherapy Vaccines 52

pharmaphorum

JANUARY 27, 2023

It’s wise advice from the “Sage of Omaha”; indeed, one highly respected financial newspaper began its 2023 predictions by conceding that it had been wrong on five major counts for 2022. About the author Richard Saynor was appointed CEO of Sandoz in 2019, a Novartis generics and biosimilars division.

Packaging 105

Packaging Biosimilars Vaccines 105

pharmaphorum

OCTOBER 20, 2021

In the first half the company had suggested diagnostic sales may start to flag in the latter half of the year as vaccinations started to bring COVID-19 infections under control, but it now expects high demand to continue into 2022. Diagnostics sales rose 39% to CHF 13.3 billion ($14.4 Group sales rose 8% to CHF 46.7

Biosimilars 98

Biosimilars Vaccines 98

European Pharmaceutical Review

AUGUST 21, 2023

According to Eli Lilly in early August 2023, its new products (select products launched since 2022: Jaypirca, Mounjaro and Omvoh) contributed $1.00 Revenue for Eli Lilly’s growth products (select products launched prior to 2022, including Jardiance, Retevmo, Taltz and Verzenio) increased 16 percent to $4.93 billion in Q2 2023.

Biosimilars 98

Biosimilars Diabetes Vaccines 98

European Pharmaceutical Review

OCTOBER 27, 2022

Ahead of the world’s largest pharma event, CPHI Frankfurt – hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics outsourcing and contract manufacturing organisastions (CMOs) in 2023. percent in 2022.

Biosimilars 98

Biosimilars Vaccines Drug Development 98

PharmaShots

APRIL 13, 2023

and became a leader in the medical device industry Novartis raised its sales by 16% and acquired Alcon (ophthalmic business), Genoptix (oncology business), and an 85% stake in Zhejiang Tianyuan (vaccine business) Bayer recorded a revenue of $49B as its pharmaceutical business posted an encouraging performance in the emerging market.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

covered insulin product or vaccine). Each phase-in program requires the manufacturer to have had a Coverage Gap Discount Program agreement in effect in 2021, and only covers applicable drugs that have been in the market as of August 16, 2022 (i.e., had Part D expenditures on or before August 16, 2022).

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105

pharmaphorum

APRIL 16, 2021

Even with the vaccine roll-out, further waves of COVID infection and lockdowns mean these vital drivers of launch performance remain impacted in 2021, and even beyond. It is also significantly biologic and biosimilars, although a mature market, do not yet yield cost savings as efficiently as small molecule generics do.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies Vaccines Documentation 95

pharmaphorum

FEBRUARY 8, 2022

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. It’s time to suspend intellectual property and break vaccine monopolies,” said the campaign group’s pharma head Tim Bierley.

Biosimilars 98

Biosimilars Vaccines 98

Express Pharma

JULY 10, 2024

India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. Today, it is a key player in the global pharma landscape. billion monthly.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

European Pharmaceutical Review

DECEMBER 6, 2022

According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 trillion in Q2 2022 to $3.14 trillion in Q3 2022. percent from $3.45 percent and 16.2

Vaccines 96

Vaccines Biosimilars 96

European Pharmaceutical Review

NOVEMBER 14, 2022

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. Read highlights from the CHMP’s September 2022 meeting. COVID-19 update. CHMP’s safety update.

Vaccines 98

Vaccines Biosimilars Generic Medicine 98

Pharma in Brief

JANUARY 10, 2024

It now contemplates IT platforms ( e.g. , social media) and applies to drugs for use in humans as well as medical devices, natural health products, biologics, vaccines, and animal health products. We anticipate that the government will continue to advance the Digital Charter Implementation Act, 2022 (Bill C-27). Rare disease strategy.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

Pharmaceutical Technology

FEBRUARY 8, 2023

The 13 top players experienced significant growth over 2022 despite the decline in demand for COVID-19 vaccines and therapeutics, as well as uncertainty surrounding pricing due to the newly passed Inflation Reduction Act in the US. billion on Dec 31, 2022. Merck & Co. Merck & Co. billion to $281.3 to $365.84.

Vaccines 78

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 78

Pharmaceutical Technology

APRIL 4, 2023

Andhra Pradesh’s pharma sector attracted investments of over $2.3bn in 2022, according to data from the state industries department. Although the region specialises in generics production, it also produces novel drugs: Telangana makes the API for 37 innovator or biosimilar drugs sold in the US and EU, and Andhra Pradesh makes API for 26.

Vaccines 52

Vaccines Biosimilars 52

European Pharmaceutical Review

SEPTEMBER 21, 2022

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1

Vaccines 98

Vaccines Generic Medicine Biosimilars 98

Drug Channels

OCTOBER 10, 2023

Drug Distribution Industry Gaining from Anti-Obesity Drugs and Provider-Administered Biosimilars (press release) We’re offering special discounted pricing if you order before October 20, 2023! addresses the Inflation Reduction Act of 2022. which examines the distribution of COVID-19 vaccines and therapeutics. and Section 6.4.3.

Specialty Pharmacies 40

Specialty Pharmacies Biosimilars Pharmaceutical Manufacturing Documentation 40

pharmaphorum

APRIL 21, 2022

Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Despite an increase in overall spending, costs per prescription on average are flat or slightly declining, says the US Medicines Trends 2022 Report.

Vaccines 52

Vaccines Biosimilars 52

Quality Matters

APRIL 4, 2023

USP standards build trust in biologics and biosimilars The field of biologics is vast and growing, with tremendous potential to improve patients’ lives and public health. By 2022, that time was nearly cut in half, at nine to 12 months, and even shorter development timelines are expected in the next few years.

Biosimilars 52

Biosimilars Vaccines Drug Development Diabetes 52

European Pharmaceutical Review

APRIL 3, 2023

It is the eighth vaccine recommended in the European Union (EU) for COVID-19. The CHMP adopted a positive opinion for Epysqli (eculizumab), a biosimilar medicine for paroxysmal nocturnal haemoglobinuria. CHMP’s January 2023 meeting highlights… Read the EMA’s human medicines highlights 2022 report.

Vaccines 98

Vaccines Chemotherapy Generic Medicine Biosimilars 98

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

DECEMBER 9, 2022

Rankings 2022. The company is ranked in the M&A, PRODUCT LAUNCHES and RESEARCH AND DEVELOPMENT categories in the 2022 Pharmaceutical Technology Excellence Rankings. The company is ranked in the M&A, PRODUCT LAUNCHES and RESEARCH AND DEVELOPMENT categories in the 2022 Pharmaceutical Technology Excellence Rankings.

Vaccines 52

Vaccines Biosimilars Compounding Packaging 52

FDA Law Blog: Biosimilars

JUNE 2, 2023

PhRMA successfully challenged that amendment, and on May 17, 2022, the United States District Court for the District of Columbia ordered that the 2020 rule be vacated and set aside. Vaccine”: Because vaccines are excluded from the MDRP, CMS proposes to define them solely for purposes of the MDRP.

Labelling 59

Labelling Vaccines Drug Pricing Immunization 59

Pharmaceutical Technology

NOVEMBER 3, 2022

There, Boehringer had earlier warned of the impending alteplase shortage in April 2022. But since these generics or biosimilars are often not too profitable, manufacturers require incentives, say Beavers and Page. Authorities from individual EU member states, like those from Czechia, have shared their individual warnings.

Dosage 111

Dosage Biosimilars Documentation Hospitals 111

PharmaShots

APRIL 3, 2023

at current exchange rates In Oct 2022, the acquisition was initiated and the transaction is expected to be adjusted per share by $0.07 Date - Jan 04, 2023 Product – N/A The acquisition is completed from a shareholder group led by Nordic Capital, in an all-cash transaction valued at $2.8B events/100 patient-yrs.) The authorization incl.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

European Pharmaceutical Review

FEBRUARY 17, 2023

The European Medicines Agency (EMA) has released a report detailing its Human Medicines Highlights 2022. The document contains an overview of the agency’s key recommendations in 2022. Human medicines highlights 2022 – additional details Public health emergencies remained a key priority for the European Medicines Agency in 2022.

Documentation 98

Documentation Biosimilars Diabetes Vaccines 98

RX Note

FEBRUARY 23, 2023

. - Drug registration number Medicines (Advertisement & Sale) Act 1956 and Regulations - To learn prohibitions of medicine advertisement and Medicine Advertisement Board Registration of Pharmacists Act 1951 and Regulations - Pharmacy Board Malaysia and legislation aspects of provisional, full and temporary registration Code of Ethics for Pharmacists (..)

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58

Big Molecule Watch

MARCH 30, 2023

12, 2022 Executive Order on “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.” Biotechnology and Biomanufacturing ,” the White House recently announced several biotech-related “bold goals” to advance the environmental, agricultural, economic, health, and science fields.

Biosimilars 49

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Vaccines 49